258 related articles for article (PubMed ID: 31058802)
1. Nanomedicines for the Delivery of Biologics.
Wahlich J; Desai A; Greco F; Hill K; Jones AT; Mrsny RJ; Pasut G; Perrie Y; Seib FP; Seymour LW; Uchegbu IF
Pharmaceutics; 2019 May; 11(5):. PubMed ID: 31058802
[TBL] [Abstract][Full Text] [Related]
2. Transport of nanomedicines across the blood-brain barrier: Challenges and opportunities for imaging and therapy.
van den Broek SL; Shalgunov V; Herth MM
Biomater Adv; 2022 Oct; 141():213125. PubMed ID: 36182833
[TBL] [Abstract][Full Text] [Related]
3. Evolution of drug delivery systems: From 1950 to 2020 and beyond.
Park H; Otte A; Park K
J Control Release; 2022 Feb; 342():53-65. PubMed ID: 34971694
[TBL] [Abstract][Full Text] [Related]
4. Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges.
Khaitan D; Reddy PL; Ningaraj N
Curr Clin Pharmacol; 2018; 13(2):110-119. PubMed ID: 29651960
[TBL] [Abstract][Full Text] [Related]
5. Lipid Nanoparticle-mRNA Formulations for Therapeutic Applications.
Wang C; Zhang Y; Dong Y
Acc Chem Res; 2021 Dec; 54(23):4283-4293. PubMed ID: 34793124
[TBL] [Abstract][Full Text] [Related]
6. mRNA delivery technologies: Toward clinical translation.
Gómez-Aguado I; Rodríguez-Castejón J; Beraza-Millor M; Rodríguez-Gascón A; Del Pozo-Rodríguez A; Solinís MÁ
Int Rev Cell Mol Biol; 2022; 372():207-293. PubMed ID: 36064265
[TBL] [Abstract][Full Text] [Related]
7. Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012).
Foffi G; Pastore A; Piazza F; Temussi PA
Phys Biol; 2013 Aug; 10(4):040301. PubMed ID: 23912807
[TBL] [Abstract][Full Text] [Related]
8. Innate and adaptive immune responses toward nanomedicines.
Viana IMO; Roussel S; Defrêne J; Lima EM; Barabé F; Bertrand N
Acta Pharm Sin B; 2021 Apr; 11(4):852-870. PubMed ID: 33747756
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in siRNA delivery mediated by lipid-based nanoparticles.
Yonezawa S; Koide H; Asai T
Adv Drug Deliv Rev; 2020; 154-155():64-78. PubMed ID: 32768564
[TBL] [Abstract][Full Text] [Related]
10. Nanomedicines: current status and future perspectives in aspect of drug delivery and pharmacokinetics.
Choi YH; Han HK
J Pharm Investig; 2018; 48(1):43-60. PubMed ID: 30546919
[TBL] [Abstract][Full Text] [Related]
11. Actively targeted nanomedicines for precision cancer therapy: Concept, construction, challenges and clinical translation.
Gu W; Meng F; Haag R; Zhong Z
J Control Release; 2021 Jan; 329():676-695. PubMed ID: 33022328
[TBL] [Abstract][Full Text] [Related]
12. Delivery Strategies for mRNA Vaccines.
Ramachandran S; Satapathy SR; Dutta T
Pharmaceut Med; 2022 Feb; 36(1):11-20. PubMed ID: 35094366
[TBL] [Abstract][Full Text] [Related]
13. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
14. Cancer nanomedicine: a review of recent success in drug delivery.
Tran S; DeGiovanni PJ; Piel B; Rai P
Clin Transl Med; 2017 Dec; 6(1):44. PubMed ID: 29230567
[TBL] [Abstract][Full Text] [Related]
15. Lipid nanoparticles for targeted delivery of anticancer therapeutics: Recent advances in development of siRNA and lipoprotein-mimicking nanocarriers.
Yaghmur A; Østergaard J; Mu H
Adv Drug Deliv Rev; 2023 Dec; 203():115136. PubMed ID: 37944644
[TBL] [Abstract][Full Text] [Related]
16. A review of the current scientific and regulatory status of nanomedicines and the challenges ahead.
Hock SC; Ying YM; Wah CL
PDA J Pharm Sci Technol; 2011; 65(2):177-95. PubMed ID: 21502077
[TBL] [Abstract][Full Text] [Related]
17. Lipid Delivery Systems for Nucleic-Acid-Based-Drugs: From Production to Clinical Applications.
Barba AA; Bochicchio S; Dalmoro A; Lamberti G
Pharmaceutics; 2019 Jul; 11(8):. PubMed ID: 31344836
[TBL] [Abstract][Full Text] [Related]
18. Safety profile of RNAi nanomedicines.
Barros SA; Gollob JA
Adv Drug Deliv Rev; 2012 Dec; 64(15):1730-7. PubMed ID: 22732527
[TBL] [Abstract][Full Text] [Related]
19. Amphiphilic Dendrimer Vectors for RNA Delivery: State-of-the-Art and Future Perspective.
Chen J; Zhu D; Liu X; Peng L
Acc Mater Res; 2022 May; 3(5):484-497. PubMed ID: 35782755
[TBL] [Abstract][Full Text] [Related]
20. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
